Verve Therapeutics Past Earnings Performance
Past criteria checks 0/6
Verve Therapeutics's earnings have been declining at an average annual rate of -38.5%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 133.9% per year.
Key information
-38.5%
Earnings growth rate
63.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 133.9% |
| Return on equity | -33.4% |
| Net Margin | -1,701.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28
Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Revenue & Expenses BreakdownBeta
How Verve Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12 | -200 | 50 | 0 |
| 30 Sep 23 | 8 | -193 | 49 | 0 |
| 30 Jun 23 | 5 | -192 | 47 | 0 |
| 31 Mar 23 | 3 | -179 | 43 | 0 |
| 31 Dec 22 | 2 | -157 | 38 | 0 |
| 30 Sep 22 | 1 | -148 | 33 | 0 |
| 30 Jun 22 | 0 | -125 | 29 | -25 |
| 31 Mar 22 | 0 | -137 | 24 | -11 |
| 31 Dec 21 | 0 | -120 | 19 | 0 |
| 30 Sep 21 | 0 | -113 | 14 | 16 |
| 30 Jun 21 | 0 | -99 | 10 | 48 |
| 31 Mar 21 | 0 | -53 | 7 | 40 |
| 31 Dec 20 | 0 | -46 | 5 | 0 |
Quality Earnings: VERV is currently unprofitable.
Growing Profit Margin: VERV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VERV is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.
Accelerating Growth: Unable to compare VERV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: VERV has a negative Return on Equity (-33.37%), as it is currently unprofitable.